Drugs / LM103

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 04 trials
Phase 0 NCT06697665 Jan 2024 → Jan 2026 overdue solid adenocarcinoma with mucin production Suzhou BlueHorse Therapeutics Co., Ltd. Recruiting No outcome recorded
Phase 0 NCT05971576 Aug 2023 → Apr 2026 overdue cancer Suzhou BlueHorse Therapeutics Co., Ltd. Not yet recruiting No outcome recorded
Phase 0 NCT05971589 Aug 2023 → Apr 2026 overdue cancer Suzhou BlueHorse Therapeutics Co., Ltd. Not yet recruiting No outcome recorded
Phase 0 NCT05941936 May 2023 → Feb 2025 Suzhou BlueHorse Therapeutics Co., Ltd. Unknown No outcome recorded
Phase 11 trial
Phase 1 NCT05366478 May 2022 → May 2024 overdue cervical carcinoma, melanoma, non-small cell lung carcinoma Suzhou BlueHorse Therapeutics Co., Ltd. Recruiting No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02414945 May 2015 → Oct 2020 malignant pleural mesothelioma University Health Network, Toronto Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as LM103 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05941936
3

NCT06697665

NCT05971576

NCT05971589

Known as Autologous tumor infiltrating lymphocytes (TILs) ClinicalTrials.gov intervention name — accepted as the source's own label NCT02414945
1

NCT05366478

Action Deplete “TILs are a type of white blood cells that recognizes tumor cells and enter them which causes the tumor cells to break down.” NCT02414945
Modality Cell therapy “The investigational infusion product consists of autologous, in vitro-expanded tumor-infiltrating lymphocytes (TILs).” NCT02414945
Route Intravenous “The cells are given intravenously over a 20-30 minute infusion.” NCT02414945